zˈaɪpɪtˌæmæɡ pˈɪɾɐvˌæstɐtˌɪn mæɡnˈiːziəm, ɐ fˌɑːɹmɐsˈuːɾɪkəl ɔːltˈɜːnətˌɪv tə lˈɪvəlˌoʊ, wʌz ɐpɹˈuːvd fɔːɹ jˈuːs ɪnðə juːnˈaɪɾᵻd stˈeɪts baɪ ðɪ ˌɛfdˌiːˈeɪ ɪn tˈuː θˈaʊzənd sˈɛvəntˌiːn.
Zypitamag (pitavastatin magnesium), a pharmaceutical alternative to Livalo, was approved for use in the United States by the FDA in 2017.